

Bruscaggin A, Terzi di Bergamo L, Spina V, et al. Circulating tumor DNA for comprehensive noninvasive monitoring of lymphoma treated with ibrutinib plus nivolumab. *Blood Adv.* 2021;5(22):4674-4685.

Page 4679: In Figure 3E-H, the greater-than and less-than signs for the cutoff of 1900 hGE/mL were reversed. Red should correspond to <1900 hGE/mL, not >1900 hGE/mL; blue should correspond to >1900 hGE/mL, not <1900 hGE/mL. In the legend, red should correspond to <1900 hGE/mL, not >1900 hGE/mL; blue should correspond to >1900 hGE/mL, not ≤ 1900 hGE/mL. The corrected Figure 3 is shown below.




Figure 3. Kaplan-Meier curves of PFS stratified according to the pretreatment *TP53* status and pretreatment ctDNA load. All cohorts stratified by *TP53* mutation status (A), relapsed FL stratified by *TP53* mutation status (B), relapsed DLBCL stratified by *TP53* mutation status (C), and RS stratified by *TP53* mutation status (D). Red: mutated (_{MUT}); blue: wild-type (_{WT}). All cohorts stratified by ctDNA load measured in haploid genomic equivalents per mL of plasma (E), relapsed FL stratified by ctDNA load (F), relapsed DLBCL stratified by ctDNA load (G), and RS stratified by ctDNA load (H). Red: ctDNA load <1900 hGE/mL of plasma; blue: ctDNA load >1900 hGE/mL of plasma.

The publisher apologizes for the errors.

<https://doi.org/10.1182/bloodadvances.2022007909>

© 2023 by The American Society of Hematology. Licensed under [Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International \(CC BY-NC-ND 4.0\)](#), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Downloaded from <http://ashpublications.net/bloodadvances/article-pdf/7/1/159/2028770/blooda-1370-main.pdf> by guest on 08 June 2024